Richard Phoon

1.1k total citations · 1 hit paper
27 papers, 610 citations indexed

About

Richard Phoon is a scholar working on Nephrology, Rheumatology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Richard Phoon has authored 27 papers receiving a total of 610 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Nephrology, 8 papers in Rheumatology and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Richard Phoon's work include Renal Diseases and Glomerulopathies (11 papers), Chronic Kidney Disease and Diabetes (7 papers) and Systemic Lupus Erythematosus Research (6 papers). Richard Phoon is often cited by papers focused on Renal Diseases and Glomerulopathies (11 papers), Chronic Kidney Disease and Diabetes (7 papers) and Systemic Lupus Erythematosus Research (6 papers). Richard Phoon collaborates with scholars based in Australia, United States and United Kingdom. Richard Phoon's co-authors include A. Richard Kitching, Stephen R. Holdsworth, Joshua D. Ooi, David W. Johnson, Jonathan C. Craig, Allison Tong, Pamela Lopez‐Vargas, Nigel D. Toussaint, Steven J. Chadban and Yvonne Shen and has published in prestigious journals such as Kidney International, Journal of the American Society of Nephrology and American Journal Of Pathology.

In The Last Decade

Richard Phoon

24 papers receiving 598 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy

2024 51 citations Richard Lafayette, Sean Barbour et al. Kidney International profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Richard Phoon Australia	12	282	170	83	82	62	27	610
Susan F. Massengill United States	15	472 1.7×	59 0.3×	78 0.9×	33 0.4×	55 0.9×	41	837
Keng Thye Woo Singapore	15	437 1.5×	79 0.5×	133 1.6×	19 0.2×	77 1.2×	81	777
Dominick Latrémouille-Viau United States	15	108 0.4×	130 0.8×	115 1.4×	15 0.2×	90 1.5×	73	845
Keisha L. Gibson United States	16	594 2.1×	207 1.2×	88 1.1×	54 0.7×	78 1.3×	53	1.1k
Ana Huerta Spain	14	181 0.6×	77 0.5×	80 1.0×	11 0.1×	32 0.5×	40	489
Luiz Felipe Santos Gonçalves Brazil	17	211 0.7×	92 0.5×	122 1.5×	30 0.4×	112 1.8×	48	856
Donal J. Sexton Ireland	15	177 0.6×	49 0.3×	75 0.9×	14 0.2×	103 1.7×	68	671
H.S. Wong Malaysia	11	239 0.8×	51 0.3×	32 0.4×	39 0.5×	25 0.4×	43	484
Melvin Madsen Denmark	10	255 0.9×	87 0.5×	98 1.2×	37 0.5×	28 0.5×	28	812
Stephanie Stringer United Kingdom	13	208 0.7×	43 0.3×	35 0.4×	30 0.4×	42 0.7×	21	574

Countries citing papers authored by Richard Phoon

Since Specialization

Citations

This map shows the geographic impact of Richard Phoon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard Phoon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard Phoon more than expected).

Fields of papers citing papers by Richard Phoon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard Phoon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard Phoon. The network helps show where Richard Phoon may publish in the future.

Co-authorship network of co-authors of Richard Phoon

This figure shows the co-authorship network connecting the top 25 collaborators of Richard Phoon. A scholar is included among the top collaborators of Richard Phoon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard Phoon. Richard Phoon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Barratt, Jonathan, Sean Barbour, Robert Brenner, et al.. (2025). #2859 ORIGIN 2b: changes in Gd-IgA1 and eGFR after discontinuation of atacicept treatment in IgA nephropathy. Nephrology Dialysis Transplantation. 40(Supplement_3).

Deed, Gary, et al.. (2024). Improving the Detection and Management of Kidney Health in Primary Care. Journal of Patient Experience. 11. 682765840–682765840. 3 indexed citations

Lafayette, Richard, Sean Barbour, Rubeen Israni, et al.. (2024). A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy. Kidney International. 105(6). 1306–1315. 51 indexed citations breakdown →

Barratt, Jonathan, Sean J. Barbour, Robert Brenner, et al.. (2024). Long-Term Results from an Open-Label Extension Study of Atacicept for the Treatment of IgA Nephropathy. Journal of the American Society of Nephrology. 36(4). 679–687. 15 indexed citations

Tunnicliffe, David J., Suetonia C. Palmer, Karam Kostner, et al.. (2024). Australian and New Zealand Living Guideline cholesterol‐lowering therapy for people with chronic kidney disease (CARI Guidelines): Reducing the evidence‐practice gap. Nephrology. 29(8). 495–509. 2 indexed citations

Barratt, Jonathan, Sean Barbour, Robert Brenner, et al.. (2024). Long-Term Results from the ORIGIN Phase 2b Study of Atacicept for the Treatment of IgA Nephropathy (IgAN). Journal of the American Society of Nephrology. 35(10S). 1 indexed citations

Barratt, Jonathan, Bart Maes, Celia J. F. Lin, et al.. (2024). WCN24-1294 ATACICEPT REDUCES HEMATURIA AND SERUM GD-IGA1, BOTH ASSOCIATED WITH LONG-TERM RENAL OUTCOMES IN IGA NEPHROPATHY: 36-WEEK RESULTS FROM THE PHASE 2B ORIGIN STUDY. Kidney International Reports. 9(4). S158–S158.

Lafayette, Richard, Bart Maes, Celia J. F. Lin, et al.. (2023). #3848 ORIGIN TRIAL: 24-WK PRIMARY ANALYSIS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PH2B STUDY OF ATACICEPT IN PATIENTS WITH IGAN. Nephrology Dialysis Transplantation. 38(Supplement_1). 11 indexed citations

Phoon, Richard, Nigel D. Toussaint, John T. Kearns, et al.. (2022). Caring for Australians and New Zealanders With Kidney Impairment Guidelines: Rapid Development of Urate Lowering Therapy Guidelines for People With CKD. Kidney International Reports. 7(12). 2563–2574. 5 indexed citations

10.

Lopez‐Vargas, Pamela, Allison Tong, Richard Phoon, et al.. (2014). Knowledge deficit of patients with stage 1–4 CKD: A focus group study. Nephrology. 19(4). 234–243. 72 indexed citations

11.

Langham, Robyn G., Rinaldo Bellomo, Zoltán Endre, et al.. (2014). KHA‐CARI guideline: KHA‐CARI adaptation of the KDIGO Clinical Practice Guideline for Acute Kidney Injury. Nephrology. 19(5). 261–265. 27 indexed citations

12.

Johnson, David W., Maria Chan, Richard Phoon, et al.. (2013). KHA‐CARI Guideline: Early chronic kidney disease: Detection, prevention and management. Nephrology. 18(5). 340–350. 132 indexed citations

13.

Wang, Yuan Min, Vincent Lee, Richard Phoon, et al.. (2012). DEC205-DC targeted DNA vaccines to CX3CR1 and CCL2 are potent and limit macrophage migration.. PubMed. 5(1). 24–33. 7 indexed citations

14.

Summers, Shaun A., Richard Phoon, Joshua D. Ooi, Stephen R. Holdsworth, & A. Richard Kitching. (2011). The IL-27 Receptor Has Biphasic Effects in Crescentic Glomerulonephritis Mediated Through Th1 Responses. American Journal Of Pathology. 178(2). 580–590. 18 indexed citations

15.

Tong, Allison, Pamela Lopez‐Vargas, Martin Howell, et al.. (2011). Consumer involvement in topic and outcome selection in the development of clinical practice guidelines. Health Expectations. 15(4). 410–423. 44 indexed citations

16.

Summers, Scott A., et al.. (2011). Signal transducer and activation of transcription 6 (STAT6) regulates T helper type 1 (Th1) and Th17 nephritogenic immunity in experimental crescentic glomerulonephritis. Clinical & Experimental Immunology. 166(2). 227–234. 12 indexed citations

17.

Phoon, Richard, A. Richard Kitching, Lynelle K. Jones, & Stephen R. Holdsworth. (2009). Atorvastatin enhances humoral immune responses but does not alter renal injury in experimental crescentic glomerulonephritis. Nephrology. 14(7). 650–657.

18.

Ooi, Joshua D., Richard Phoon, Stephen R. Holdsworth, & A. Richard Kitching. (2009). IL-23, not IL-12, Directs Autoimmunity to the Goodpasture Antigen. Journal of the American Society of Nephrology. 20(5). 980–989. 99 indexed citations

19.

O'Connor, Kate, David A. Fulcher, & Richard Phoon. (2009). Development of Anti–Glomerular Basement Membrane Disease After Remission From Perinuclear ANCA-Associated Glomerulonephritis in a Patient With HLA Susceptibility. American Journal of Kidney Diseases. 55(3). 566–569. 5 indexed citations

20.

Phoon, Richard, A. Richard Kitching, Dragana Odobasic, et al.. (2008). T-bet Deficiency Attenuates Renal Injury in Experimental Crescentic Glomerulonephritis. Journal of the American Society of Nephrology. 19(3). 477–485. 58 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact